AIM2 and acquired idiopathic inflammatory myopathy: demonstrated through transcriptome microarray technology and immunoblotting that immunosuppressive therapy can downregulate the expression of AIM2 and caspase-1 in skeletal muscle samples from patients with DM and PM, suggesting that this may be a potential therapeutic strategy to reduce inflammation in IIM patients.